EUVIMEDEUVIMED entdecken
Crossref

A Hybrid Alloying Nanozyme‐Glutathione Inhibitor Co‐Delivery System Initiates a Dual‐Disruption on Cancer Redox Homeostasis

Jue Hou, Hanxiao Bao, Yu Wang, Qiaomei Zhou, Jiayi Chen, Guohua Pan, Guoqiao Xu, Jinguo Zhang, Guping Tang, Hongzhen Bai iD

Small · 2025

DOI: 10.1002/smll.202407555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2025. Verfasst von Jue Hou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Zhejiang University, Hangzhou, 310058, China. Hauptthemen laut MEDLINE: Oxidation-Reduction, Homeostasis, Glutathione, Alloys. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Altered redox homeostasis has long been observed in cancer cells, which can be exploited for therapeutic benefits. However, reactive oxygen species (ROS) pleiotropy coupling with reductive adaptation in cancer cells poses a formidable challenge for redox dyshomeostasis‐based cancer therapy. Herein, a AuPd alloying nanozyme‐glutathione (GSH) biosynthesis inhibitor co‐delivery system (B‐BMES) is developed using dendritic SiO 2 as a matrix to target cancer redox homeostasis. By optimizing element composition, the alloying nanozyme in B‐BMES exhibits a potent peroxidase (POD)‐like activity to trigger ROS insults‐mediated redox dyshomeostasis. Such a POD functionality is attributed to the optimized electronic structure and catalytic activity. Simultaneously, the B‐BMES abrogates the reductive adaptation by exerting its molecule‐targeted GSH suppression, thereby achieving a dual‐disruption on cancer redox homeostasis. Camouflaging B‐BMES with tumor‐homologous cytomembrane, a hybrid nanosystem with biological stability and tumor‐targeting ability is further fabricated, which initiates a safe, precise redox disruption‐based cancer therapy and sensibilizes standard chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oxidation-ReductionHomeostasisGlutathioneAlloysNeoplasmsDrug Delivery SystemsHumansCell Line, TumorReactive Oxygen SpeciesAnimalsSilicon DioxideMice

Stichwörter der Autor:innen

cell membranedrug deliverynanocatalytic medicineperoxidase‐like nanozyme

Substanzen

GlutathioneAlloysReactive Oxygen SpeciesSilicon Dioxide

Autor:innen und Institutionen

  • Department of Chemistry, Zhejiang University, Hangzhou, 310058, China.
  • Department of Radiology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, 310009, China.

ORCID-Profile: Hongzhen Bai

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Hou, J., Bao, H., Wang, Y., Zhou, Q., Chen, J., Pan, G., Xu, G., Zhang, J., Tang, G., & Bai, H. (2025). A Hybrid Alloying Nanozyme‐Glutathione Inhibitor Co‐Delivery System Initiates a Dual‐Disruption on Cancer Redox Homeostasis. Small. https://doi.org/10.1002/smll.202407555

Vancouver

Hou J, Bao H, Wang Y, Zhou Q, Chen J, Pan G, et al. A Hybrid Alloying Nanozyme‐Glutathione Inhibitor Co‐Delivery System Initiates a Dual‐Disruption on Cancer Redox Homeostasis. Small. 2025. doi:10.1002/smll.202407555

BibTeX
@article{Hou2025,
  author = {Hou, Jue and Bao, Hanxiao and Wang, Yu and Zhou, Qiaomei and Chen, Jiayi and Pan, Guohua and Xu, Guoqiao and Zhang, Jinguo and Tang, Guping and Bai, Hongzhen},
  title = {A Hybrid Alloying Nanozyme‐Glutathione Inhibitor Co‐Delivery System Initiates a Dual‐Disruption on Cancer Redox Homeostasis},
  journal = {Small},
  year = {2025},
  doi = {10.1002/smll.202407555}
}
Kostenlos starten →